Alcidion Group Limited (ALC) AI Stock Analysis

• Market Cap: AU$134.30M
• Dividend Yield: N/A
• Average Volume (3M): 796.98K
• Price to Earnings (P/E): 81.7
• Beta (1Y): 0.96
• Revenue Growth: 10.06%
• EPS Growth: N/A
• Country: AU
• Employees: 145
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): <0.01
• Shares Outstanding: 1,342,952,600
• 10 Day Avg. Volume: 536,053
• 30 Day Avg. Volume: 796,979
• PEG Ratio: -0.70
• Price to Book (P/B): 1.57
• Price to Sales (P/S): 3.38
• P/FCF Ratio: 24.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: AU$0.13
• Price Target Upside: 30.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: AU$0.11 ▲(12.00% Upside)

Alcidion Group Limited's strong financial performance, characterized by robust revenue growth and efficient cost management, is the most significant factor driving its score. However, the high P/E ratio suggests overvaluation, which, combined with neutral technical indicators, tempers the overall outlook.

Positive Factors

Revenue Growth

The company's strong revenue growth indicates a robust market position and increasing demand for its healthcare solutions, supporting long-term business expansion.

Cash Generation

Strong cash generation enhances financial flexibility, allowing for reinvestment in growth initiatives and providing a buffer against economic uncertainties.

Financial Stability

Low leverage risk enhances financial stability, reducing the burden of debt servicing and allowing the company to focus on strategic growth opportunities.

Negative Factors

Profitability Margins

Limited profitability margins can constrain reinvestment capabilities and shareholder returns, potentially impacting long-term growth and competitiveness.

Operational Challenges

Negative EBIT margin suggests inefficiencies in operations, which may hinder profitability and require strategic adjustments to improve cost management.

Return on Equity

Low return on equity indicates limited profitability from shareholders' investments, which may affect investor confidence and capital attraction.

Alcidion Group Limited Business Overview & Revenue Model

Company Description

Alcidion Group Limited (ASX: ALC) is an Australian technology company specializing in healthcare solutions. The company operates within the health tech sector, focusing on software development that enhances clinical decision-making, patient management, and operational efficiencies in hospitals and healthcare facilities. Its core products include the Smart Clinical Decision Support platform, which integrates clinical data to provide actionable insights, and the Patient Journey Management solutions designed to optimize patient flow and resource utilization.

How the Company Makes Money

Alcidion Group Limited generates revenue primarily through the sale of software licenses, subscriptions, and related services to healthcare providers. The company offers a recurring revenue model through annual subscriptions for its cloud-based solutions, providing a steady income stream. Key revenue streams also include implementation services, training, and support services provided to clients post-sale. Additionally, Alcidion has formed strategic partnerships with various healthcare organizations and technology firms, which enhance its market presence and can lead to new business opportunities. Factors contributing to its earnings include the increasing demand for digital health solutions, particularly in response to the challenges faced by healthcare systems globally, and ongoing investments in product development to maintain competitiveness in the evolving health tech landscape.

Alcidion Group Limited Financial Statement Overview

Summary

Alcidion Group Limited shows strong revenue growth and efficient cost management with a high gross profit margin. The company maintains a stable financial position with low debt levels, enhancing financial flexibility. Despite low profitability margins, the significant improvement in cash flow metrics highlights strong cash generation capabilities.

Income Statement

Alcidion Group Limited has shown a positive revenue growth rate of 14.45% in the latest year, indicating a strong upward trajectory. The gross profit margin is high at 88.24%, reflecting efficient cost management. However, the net profit margin is relatively low at 4.06%, suggesting limited profitability. The EBIT margin is negative, indicating operational challenges, but the EBITDA margin is positive, showing some improvement in operational efficiency.

Balance Sheet

The company maintains a very low debt-to-equity ratio of 0.016, indicating strong financial stability and low leverage risk. The return on equity is modest at 1.88%, suggesting limited profitability from shareholders' investments. The equity ratio is not provided, but the overall balance sheet reflects a stable financial position with low debt levels.

Cash Flow

Alcidion Group Limited has demonstrated a significant improvement in free cash flow growth, with a remarkable increase of 3584.97%. The operating cash flow to net income ratio is 0.28, indicating a healthy conversion of income into cash. The free cash flow to net income ratio is high at 0.98, showing strong cash generation relative to net income.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	40.79M	40.79M	37.06M	40.40M	34.35M	25.88M
Gross Profit	35.99M	35.99M	31.92M	1.25M	3.29M	3.52M
EBITDA	1.94M	1.94M	-4.50M	-1.43M	-1.58M	-474.00K
Net Income	1.65M	1.65M	-8.42M	-3.62M	-4.41M	-2.24M
Balance Sheet
Total Assets	115.63M	115.63M	114.46M	120.68M	128.35M	58.38M
Cash, Cash Equivalents and Short-Term Investments	17.70M	17.70M	11.80M	14.64M	17.34M	25.03M
Total Debt	1.41M	1.41M	1.70M	2.15M	2.48M	181.00K
Total Liabilities	27.82M	27.82M	27.52M	30.52M	34.40M	13.16M
Stockholders Equity	87.80M	87.80M	86.94M	90.17M	93.95M	45.22M
Cash Flow
Free Cash Flow	5.64M	5.64M	-7.18M	-285.00K	685.00K	1.23M
Operating Cash Flow	5.76M	5.76M	-7.13M	169.00K	996.00K	1.54M
Investing Cash Flow	-125.00K	-125.00K	-53.00K	-3.14M	-59.74M	-9.84M
Financing Cash Flow	-764.00K	-764.00K	4.34M	-616.00K	51.33M	17.23M

Alcidion Group Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ALC, the sentiment is Positive. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 49.18 is Neutral, neither overbought nor oversold. The STOCH value of 7.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ALC.

Alcidion Group Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALC	64 Neutral	AU$134.30M	81.67	1.89%	―	10.06%	―
PCK	55 Neutral	AU$62.69M	-6.75	-8647.54%	―	25.98%	22.10%
ONE	54 Neutral	AU$274.80M	-12.34	―	―	21.56%	-24.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BMT	51 Neutral	AU$58.12M	-9.15	-13.83%	―	3.61%	-17.03%
M7T	46 Neutral	AU$132.76M	-21.71	-12.35%	―	15.99%	22.05%
SHG	40 Underperform	AU$78.49M	-11.23	―	―	―	―

Alcidion Group Limited Corporate Events

Alcidion Expands Contract with Leidos Australia, Boosting Revenue and Market Position

Alcidion Group Limited has expanded its contract with Leidos Australia to enhance the use of its Miya Precision software, securing a total contract value of $12.3 million until June 2028. This expansion is expected to add $2.5 million to Alcidion’s annual recurring revenue, with significant revenue recognition projected for FY26, aligning with a larger contract that could extend to 2036, thus strengthening Alcidion’s market position in healthcare technology.

Alcidion to Release Q1 FY26 Results with Investor Webcast

Alcidion Group Limited announced the release of its Q1 FY26 Quarterly Cash Flow Report on 28 October 2025, accompanied by a live investor webcast featuring discussions on the quarter’s operational and commercial highlights. This announcement underscores Alcidion’s commitment to transparency and engagement with stakeholders, potentially influencing investor confidence and market positioning.

Alcidion Group Limited 2025 AGM Resolutions Announced

At its 2025 Annual General Meeting, Alcidion Group Limited announced that all resolutions were decided by poll, with the adoption of the Remuneration Report and the election of Andrew Way as a Director both carried. The approval of a 10% Placement Facility was withdrawn. These outcomes reflect Alcidion’s continued focus on strategic governance and operational decisions that align with its mission to enhance healthcare delivery.

Alcidion Reports Record Growth and Major Contracts at 2025 AGM

Alcidion Group Limited, a leader in healthcare technology solutions, announced significant achievements at its 2025 Annual General Meeting. The company reported a record-setting fiscal year with total revenue of $40.8 million, a 10% increase from the previous year, and secured $73.8 million in new contracts. Notably, Alcidion’s Miya Precision platform continues to gain traction, highlighted by a landmark $39 million contract with North Cumbria NHS Trust. The company’s financial health is robust, with no debt and a cash reserve of $17.7 million, positioning it well for further growth and innovation in the healthcare sector.

Alcidion Withdraws Resolution on Placement Facility Ahead of AGM

Alcidion Group Limited announced the withdrawal of ‘Resolution 3 – Approval of 10% Placement Facility’ from its upcoming Annual General Meeting agenda. This decision follows shareholder feedback and the company’s current lack of intention to use the additional placement capacity. The withdrawal does not affect the validity of proxy votes for other resolutions, which will proceed as planned. This move reflects Alcidion’s responsiveness to shareholder input and its current strategic focus, potentially impacting its capital management strategies.

Alcidion Expands Contract with North Cumbria NHS to Enhance Digital Healthcare Solutions

Alcidion Group Limited has announced an expansion of its contract with North Cumbria Integrated Care NHS Foundation Trust to include MediViewer, an Electronic Document Management System, into its Miya Precision Electronic Patient Record solution. This integration will provide seamless access to scanned and historical documents, enhancing clinical workflows and digital maturity. The contract, valued at approximately $6.8 million over 9.4 years, aligns with Alcidion’s strategy to support the digitization of healthcare workflows and improve patient care efficiency. The implementation of MediViewer is expected to drive regional convergence and efficiency, laying the groundwork for future adoption of emerging technologies like AI and predictive analytics.

Alcidion Group to Showcase Growth Strategy at Sydney Investor Roadshow

Alcidion Group Limited announced its participation in an investor roadshow in Sydney, aiming to engage with investors and present its growth strategy following the FY25 results. This initiative reflects Alcidion’s commitment to expanding its market presence and underscores its strategic focus on leveraging technology to transform healthcare delivery.